MaaT Pharma (EURONEXT: MAAT – the “Company”), a French late-stage biotechnology company, a pioneer in the development of drugs to restore the gut microbiota to improve the survival of cancer patients, announces today the launch of a Phase 2a clinical trial sponsored by AP-HP, evaluating MaaT013, MaaT Pharma’s most advanced microbiota drug candidate, in combination with immune checkpoint (ICI) inhibitors, ipilimumab (Yervoy ®) and nivolumab (Opdivo®), reference first-line treatments for patients with metastatic melanoma.